- Trial phase
- Phase 1
- Time to market
- VIR-5525 is in Phase 1 dose escalation with no efficacy data yet. If successful through Phase 1, Phase 2 and potentially registrational trials would follow, meaning commercial launch is likely 5+ years away under typical timelines.
- Why 2/10
- VIR-5525 is an early Phase 1 asset still in dose escalation with no scheduled binary catalyst (PDUFA, pivotal readout, or AdComm) in the next ~12 months. The next potential catalyst would be initial Phase 1 safety/efficacy data at a future medical conference, but management has not guided to a specific date. The drug is one of three TCE programs at Vir and is not the company's lead value driver.
VIR-5525 is still in Phase 1 dose escalation with no efficacy data or binary catalyst on the calendar. The next meaningful event would be initial safety/efficacy data at a future scientific conference, but management has not guided to a specific timeline. Vir's near-term stock-moving catalysts are elsewhere: the ECLIPSE Phase 3 hepatitis delta topline (Q4 2026) and VIR-5500's progression toward pivotal trials. VIR-5525 is a watch-and-wait program for now.
Price Chart
Executive Summary
VIR-5525 is an investigational EGFR-targeting dual-masked T-cell engager (TCE) being developed by Vir Biotechnology (Nasdaq: VIR) for solid tumors. It is in a Phase 1 first-in-human clinical trial (NCT06960395) as monotherapy and in combination with pembrolizumab across multiple EGFR-expressing tumor types including non-small cell lung cancer, colorectal cancer, and head and neck cancers. First patient was dosed in July 2025, and as of the Q3 2026 earnings update (November 4, 2026), the drug continues to progress through dose escalation with no efficacy data reported yet. VIR-5525 is Vir's third TCE program to enter the clinic, following VIR-5500 (PSMA, partnered with Astellas) and VIR-5818 (HER2). At this early stage with no near-term binary catalyst, VIR-5525 is a minor driver of Vir's investment thesis relative to the company's more advanced hepatitis delta and oncology programs.
How It Works
VIR-5525 is a dual-masked T-cell engager (TCE), a type of immunotherapy that works like a molecular bridge. One end grabs onto EGFR proteins on the surface of cancer cells, and the other end grabs onto CD3 proteins on immune T-cells, forcing the T-cells to attack the cancer. The 'dual-masked' design uses PRO-XTEN technology to keep the drug inactive until it reaches the tumor environment, where enzymes in the tumor remove the mask. This is intended to reduce side effects (like cytokine release syndrome) by preventing the drug from activating T-cells in healthy tissue.
Trial Status
Phase 1 first-in-human trial (NCT06960395) is actively recruiting. The study has four parts: Part 1 (monotherapy dose escalation) and Part 2 (combination with pembrolizumab dose escalation) are ongoing. As of the Q3 2026 earnings call (November 4, 2026), VIR-5525 continues to progress through dose escalation in both monotherapy and combination therapy across lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. No efficacy data or dose-expansion results have been reported. The trial plans to enroll approximately 450 participants.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1 safety and efficacy data from dose escalation (no specific date guided by management)
- Potential presentation at a future scientific conference (not yet announced)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vir Biotechnology, Inc. 8-K VIR ·Originating report